Global News and Digital Insights
for the Healthcare Industry

Eli Lilly’s Mounjaro receives a nod by USFDA for Type Two Diabetes

The US Food and Drug Administration has approved Eli Lilly’s tirzepatide, an injectable drug, for the use of improving sugar levels in blood. Mounjaro, the brand name of tirzepatide, has seen to be more effective, if taken alongside a balanced diet and exercise, than the other drugs with which it was compared in the clinical studies. Lilly informs that during the final-stage trial of Mounjaro, the anti-obesity properties were also observed. In fact, patients taking the medication lost 20% of their weight. The said drug is to be injected with the required dose once a week to regulate blood sugar levels.

Read More from Reuters

Share on facebook
Share on twitter
Share on linkedin